Calpurbatug
Alternative Names: TRL-1068Latest Information Update: 19 Jun 2026
At a glance
- Originator Trellis Bioscience
- Class Antibacterials; Monoclonal antibodies
- Mechanism of Action Bacterial biofilm inhibitors
-
Orphan Drug Status
Yes - Methicillin-resistant Staphylococcus aureus infections; Bacterial endocarditis
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Methicillin-resistant Staphylococcus aureus infections
- Preclinical Bacterial infections
Most Recent Events
- 12 Jun 2026 Trellis Bioscience plans a phase I trial for Healthy volunteers in USA (Inhalation) (NCT07644195)
- 08 Apr 2025 Phase-II clinical trials in Methicillin-resistant Staphylococcus aureus infections in USA (IV) (NCT06621251)
- 23 Oct 2024 TRL 1068 receives Fast Track designation for Bacterial endocarditis [IV,Infusion] in USA, before October 2024